BIORED
ActiveSummary
BIORED has been active since 1999 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €3.8m and a net result of -€4,146. Equity remains stable across the filed financial years (±0.2% per year). The computed 12-month bankruptcy probability is 0.4% (very low).
Group and network
Holdings and subsidiaries
1 holding · 4 subsidiaries in the treeHoldings 1
-
65.57%
All subsidiaries, including indirect ones 4
Companies in which this company or one of its subsidiaries holds more than half, or which it consolidates according to the LEI register.
NV R.E.D. LABORATORIES 65.57%3 subsidiaries
- REDRENO LLCUS 100%
PROTEA BIOPHARMA NV 99.99%1 subsidiary
- KALIDA BVNL 100%
According to the 2023 annual accounts of BIORED and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Connections & network
1 current directorThe network starts from this company’s directors. Other companies they run appear here as nodes.